salmonella
speci
consist
effect
sera
produc
discoveri
antibiot
interest
serum
therapi
treatment
infecti
diseas
wane
initi
interest
use
combin
therapi
antibiot
serum
abandon
potenti
benefit
margin
antimicrobi
chemotherapi
prove
less
toxic
effect
serum
therapi
treatment
infect
howev
dr
cohn
discoveri
purifi
antibodi
cold
ethanol
fraction
plasma
second
world
war
reviv
interest
antibodi
treatment
especi
infect
abl
treat
antibiot
fraction
procedur
stabil
product
denatur
virus
assur
uniform
antibodi
content
cohn
fraction
igg
plasma
cold
alcohol
fraction
initi
use
prophylaxi
preval
lifethreaten
infect
measl
bruton
report
first
time
use
immunoglobulin
prepar
inject
subcutan
treatment
young
boy
agammaglobulinemia
thereaft
use
immunoglobulin
inject
intramuscularli
becam
establish
standard
therapi
primari
immunodefici
last
develop
purer
safer
intraven
immunoglobulin
prepar
earli
advent
hybridoma
technolog
allow
continu
gener
larg
quantiti
monoclon
antibodi
specif
antigen
interest
gener
human
antibodi
revolution
antibodi
therapeut
monoclon
antibodi
technolog
offer
suppli
advantag
reduc
risk
advers
event
decreas
lottolot
variat
monoclon
antibodi
mab
introduc
clinic
practic
prevent
organ
reject
almost
decad
later
human
mab
palivizumab
human
mous
monoclon
antibodi
prevent
rsv
pulmonari
infect
highrisk
patient
especi
infant
licens
palivizumab
potent
polyclon
product
result
reduc
volum
administr
intramuscular
use
last
three
decad
therapeut
mab
licens
mainli
treatment
malign
rheumat
autoimmun
diseas
two
licens
infecti
diseas
palivizumab
raxibacumab
human
mab
anthrax
toxin
although
use
mab
treat
infecti
diseas
depend
discrimin
selfantigen
larg
antigen
differ
microorgan
host
pace
discoveri
develop
new
mab
infecti
diseas
limit
current
area
mab
develop
focus
viral
diseas
without
avail
vaccin
hiv
ebola
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
marburg
viru
viral
diseas
limit
effect
antivir
drug
influenza
rabi
bacteri
toxinmedi
diseas
anthrax
clostridium
difficil
coliti
clinic
set
therapeut
mab
use
nosocomialiatrogen
outbreak
exampl
new
approach
prevent
recurr
c
difficil
infect
administr
mab
c
difficil
toxin
addit
antibiot
therapi
form
passiv
immun
actoxumab
bezlotoxumab
fulli
human
monoclon
antibodi
bind
neutral
c
difficil
toxin
b
respect
doubleblind
random
placebocontrol
phase
trial
show
singl
intraven
dose
bezlotoxumab
given
standardofcar
antibiot
provid
protect
recurr
c
difficil
infect
week
superior
provid
treatment
standardofcar
antibiot
alon
therapeut
mab
appli
drug
resist
staphylococcu
aureu
vrsa
pandem
outbreak
ebola
viru
bioterror
attack
bacillu
anthraci
emerg
infecti
diseas
nipah
hendra
viru
use
highrisk
host
group
sever
diseas
respiratori
syncyti
viru
cytomegaloviru
retin
hiv
patient
hepat
c
viru
influenza
viru
anoth
applic
therapeut
mab
concern
use
adjunct
therapi
antiinflammatori
immun
modulatori
role
mab
immun
mediat
immunoglobulin
glycoprotein
molecul
produc
plasma
cell
respons
antigen
immunogen
function
antibodi
serum
contain
heterogen
immunoglobulin
pool
reflect
host
respons
endogen
microbiota
immunolog
memori
host
varieti
acquir
microbi
agent
differ
immunoglobulin
differ
structur
howev
built
basic
unit
five
class
immunoglobulin
classifi
accord
type
heavi
chain
possess
tabl
class
immunoglobulin
specif
function
defici
class
lead
particular
dysfunct
immun
system
serum
igm
predomin
acut
immun
respons
antigen
effici
complementfix
immunoglobulin
immunoglobulin
class
switch
subsequ
occur
lead
predomin
igg
respons
protect
first
infecti
attack
longterm
protect
via
memori
b
cell
secretori
iga
due
abund
mucos
secret
provid
primari
defens
mechan
mucos
infect
ige
primarili
defend
parasit
invas
immunoglobulin
togeth
cell
key
mediat
adapt
immun
defici
either
two
arm
adapt
immun
system
result
higher
host
suscept
bacteri
fungal
viral
infect
immunoglobulin
interact
understand
mechan
interact
immunoglobulin
immunomodulatori
molecul
cell
immun
system
innat
adapt
basi
understand
futur
therapeut
perspect
immunoglobulin
immunoglobulin
upon
bind
specif
antigen
stimul
signific
direct
indirect
effector
function
classic
bacteri
diseas
immunoglobulin
neutral
toxin
facilit
opson
complement
promot
bacteriolysi
viral
diseas
immunoglobulin
block
viral
entri
uninfect
cell
promot
antibodydirect
cellmedi
cytotox
natur
killer
cell
neutral
viru
alon
particip
complement
furthermor
recent
studi
demonstr
immunomodulatori
function
antibodi
includ
potenti
antibodi
therapi
reduc
damag
host
inflammatori
respons
major
infect
notabl
igg
exert
proand
antiinflammatori
activ
depend
concentr
low
dose
igg
proinflammatori
activ
requir
complement
activ
bind
fc
fragment
igg
iggspecif
receptor
innat
immun
effector
cell
result
receptor
cluster
recruit
secondari
effector
function
subsequ
activ
signal
pathway
lead
increas
intracellular
calcium
level
cell
activ
comparison
high
concentr
igg
antiinflammatori
properti
mechan
propos
mode
action
modul
express
function
interfer
activ
complement
cascad
cytokin
network
neutral
autoantibodi
regul
cell
prolifer
immunoglobulin
prepar
use
passiv
immun
standard
human
serum
immunoglobulin
avail
three
form
immun
globulin
ig
intramuscular
use
imig
intraven
use
ivig
subcutan
use
scig
imig
use
primarili
prevent
certain
infect
hepat
measl
rubella
less
commonli
treatment
antibodi
immunodefici
ivig
use
treatment
primari
secondari
antibodi
defici
mani
immunoregulatori
disord
eg
immun
thrombocytopen
purpura
kawasaki
diseas
neurolog
disord
eg
syndrom
peripher
neuriti
igsc
use
exclus
antibodi
defici
ivig
prepar
compris
pool
fraction
serum
donor
gener
cold
ethanol
precipit
provid
thu
broad
spectrum
opson
neutral
igg
antibodi
opson
neutral
igg
antibodi
content
vari
product
batch
primarili
due
differ
local
pathogen
ecolog
donor
exposur
igg
complement
protein
princip
class
opsonin
contribut
bacteri
clearanc
addit
igg
vari
amount
immunoglobulin
isotyp
especi
iga
found
ivig
prepar
regard
differ
human
igg
subclass
ivig
prepar
reflect
hierarchi
present
serum
consist
mainli
contain
much
smaller
amount
igg
subclass
product
biotest
germani
igmenrich
clinic
use
ivig
distinguish
infus
amount
princip
manufactur
process
current
igg
prepar
cold
ethanol
fraction
productspecif
addit
process
manufactur
commonest
process
viru
reduct
includ
solventsdeterg
low
ph
ph
incub
nanofiltr
chromatographi
major
qualiti
control
practic
product
process
besid
viral
reduct
includ
deplet
blood
coagul
factor
remov
igg
aggreg
sinc
aggreg
could
result
cytokin
releas
syndrom
owe
ubiquit
activ
innat
immun
effector
cell
via
activ
igg
aggreg
absent
major
ivig
prepar
howev
depend
provid
batch
igg
found
dimer
form
ivig
prepar
two
major
indic
immunoglobulin
use
igg
replac
therapi
antiinflammatori
therapi
varieti
acut
chronic
autoimmun
diseas
apart
immunoglobulin
replac
therapi
current
licens
applic
immunoglobulin
ivig
administr
includ
syndrom
kawasaki
diseas
chronic
inflammatori
demyelin
polyneuropathi
licens
indic
howev
account
approxim
worldwid
immunoglobulin
sale
immunoglobulin
administr
offlabel
use
immunoglobulin
infecti
diseas
involv
passiv
transfer
antibodi
prepostexposur
prophylaxi
treatment
passiv
immun
provid
tempor
immun
unimmun
individu
either
prophylact
therapeut
differ
form
passiv
immunotherapi
shown
tabl
technolog
ethanol
fraction
plasma
result
product
use
treatment
prophylaxi
infecti
diseas
tabl
human
immun
sera
fewer
advers
effect
concern
avail
potenc
consist
tabl
summar
advers
reaction
immunoglobulin
use
prevent
treatment
infecti
diseas
administr
immunoglobulin
indic
major
patient
primari
immun
defici
patient
combin
immun
defici
secondari
immun
defici
signific
antibodi
defici
benefit
replac
immunoglobulin
therapi
prevent
infect
patient
antibodi
defici
well
establish
pertain
reduct
incid
sever
infect
prevent
longterm
deterior
organ
function
primari
immun
defici
pidd
one
us
food
drug
administr
fda
approv
indic
immunoglobulin
therapi
pidd
involv
antibodymedi
immun
howev
individu
disord
differ
immunopathogenesi
term
number
b
cell
blood
bcell
function
moreov
persist
endogen
antibodi
product
vari
specif
condit
within
individu
disord
tabl
describ
pidd
immunoglobulin
replac
may
efficaci
recommend
immunoglobulin
replac
treatment
primari
secondari
immun
defici
shown
tabl
main
indic
primari
antibodi
defici
includ
agammaglobulinemia
autosom
recess
xlink
common
variabl
immunodefici
disord
rare
antibodi
defici
igg
subclass
defici
may
manag
immunoglobulin
replac
immunodefici
trial
month
may
indic
substanti
infect
burden
contrari
select
iga
defici
immunoglobulin
replac
requir
recommend
anaphylact
reaction
may
occur
ivig
infus
combin
immunodefici
antibodi
defici
also
benefit
immunoglobulin
therapi
defect
cellmedi
immun
correct
hematopoiet
stem
cell
transplant
howev
bcell
function
restor
univers
transplant
immunoglobulin
therapi
may
continu
import
patient
receiv
thorough
evalu
start
immunoglobulin
therapi
especi
partial
antibodi
defect
american
academi
allergi
asthma
immunolog
base
review
evid
recommend
pidd
dose
mgkg
ivig
everi
week
titrat
dose
interv
infus
achiev
trough
igg
level
least
greater
mgdl
agammaglobulinem
patient
howev
recent
evid
suggest
goal
igg
replac
therapi
reduc
prevent
seriou
recurr
infect
instead
aim
achiev
specif
igg
level
clinician
identifi
patient
pidd
individu
biolog
igg
level
patient
achiev
best
clinic
outcom
instead
tri
reach
specif
igg
level
two
mode
igg
replac
ivig
scig
signific
pharmacokinet
differ
import
know
choos
mode
igg
deliveri
switch
ivig
scig
scig
caus
sustain
releas
igg
thu
attain
higher
igg
trough
level
mode
deliveri
may
benefit
patient
show
increas
risk
infect
week
receiv
ivig
experi
extrem
lethargi
period
ivig
achiev
higher
peak
level
higher
obtain
sc
infus
mode
deliveri
usual
initi
prefer
patient
pidd
symptomat
present
pneumonia
seriou
infecti
sepsi
present
pneumonia
medic
problem
sepsi
ivig
also
use
number
diseas
caus
secondari
humor
immunodefici
major
secondari
immunodefici
use
ivig
support
anecdot
report
bcell
chronic
lymphocyt
leukemia
cll
pediatr
hiv
infect
fdaapprov
indic
cll
hiv
infect
common
complic
ivig
shown
use
prophylact
therapi
infect
patient
administr
ivig
cll
patient
hypogammaglobulinemia
shown
decreas
rate
bacteri
infect
howev
decis
analysi
model
show
decreas
might
improv
length
qualiti
treat
patient
live
furthermor
extraordinarili
expens
prophylact
administr
ivig
cll
patient
studi
extens
thu
guidelin
defin
patient
popul
would
benefit
treatment
also
optim
dose
time
ivig
administr
remain
defin
expert
support
use
ivig
select
case
depend
histori
patient
especi
patient
ivig
shown
work
past
ivig
therapi
togeth
antivir
therapi
benefici
infant
children
aid
hypogammaglobulinemia
two
bacteri
infect
previou
year
indic
ivig
therapi
hivinfect
patient
includ
sever
parvoviru
measl
infect
howev
import
note
studi
occur
era
highli
activ
antiretrovir
treatment
hiv
ivig
util
allogen
bone
marrow
transplant
bmt
attempt
decreas
incid
cytomegaloviru
cmv
infect
infect
due
pathogen
graftversushost
diseas
gvhd
immunoglobulin
use
set
bmt
fda
approv
rational
use
ivig
transplant
administr
passiv
antibodi
may
prevent
infect
immunocompromis
patient
especi
infect
caus
cmv
sever
random
control
trial
provid
basi
recommend
ivig
allogen
bmt
metaanalysi
trial
found
signific
reduct
fatal
cmv
infect
cmv
pneumonia
noncmv
interstiti
pneumonia
transplantrel
mortal
among
patient
receiv
prophylact
ivig
improv
surviv
report
studi
recent
metaanalysi
show
ivig
hyperimmun
cmvivig
effect
reduct
allcaus
mortal
collect
data
regard
benefit
prophylact
administr
ivig
bmt
remain
controversi
contradictori
addit
current
consensu
type
schedul
dose
patient
benefit
ivig
subsequ
studi
suggest
doubl
prophylaxi
consist
highdos
ivig
ganciclovir
success
either
treatment
alon
revers
cmv
pneumonia
patient
bmt
american
societi
blood
marrow
transplant
recommend
routin
use
ivig
hematopoiet
cell
transplant
recipi
prophylaxi
cmv
diseas
bacteri
infect
within
first
day
transplant
patient
sever
hypogammaglobulinemia
igg
mgdl
ivig
prophylaxi
bacteri
infect
may
consid
ivig
dose
frequenc
patient
individu
maintain
trough
serum
igg
concentr
mgdl
routin
use
ivig
appear
offer
littl
benefit
patient
malign
undergo
hlaident
sibl
bmt
given
landscap
patient
receiv
bmt
evolv
like
avail
data
outdat
updat
random
trial
warrant
inform
clinic
practic
gvhd
infect
major
complic
allogen
bmt
vitro
vivo
experiment
model
show
prevent
acut
gvhd
ivig
mediat
induct
apoptosi
activ
alloreact
express
donor
cell
reduc
amount
produc
donor
cell
ivig
shown
decreas
sever
acut
gvhd
recipi
allogen
bmt
contrari
administr
ivig
prophylaxi
effect
incid
mortal
chronic
gvhd
bmt
consensu
optim
dose
ivig
appear
incid
acut
gvhd
less
patient
receiv
higher
dose
ivig
benefit
ivig
appear
correl
igg
trough
level
acut
gvhd
less
frequent
among
patient
achiev
maximum
serum
igg
level
mgdl
administr
ivig
trough
serum
igg
level
mgdl
associ
less
sever
acut
gvhd
last
decad
ivig
usag
solid
organ
transplant
increas
significantli
encourag
data
role
ivig
treatment
antibodymedi
reject
desensit
hla
andor
abo
antigen
well
prevent
treatment
infecti
complic
patient
undergo
solid
organ
transplant
also
evid
ivig
may
use
treatment
autoimmun
cytopenia
solid
organ
transplant
dose
ivig
empir
although
higher
replac
therapi
especi
treatment
antibodymedi
reject
dose
gmkg
use
higher
dose
ivig
relat
higher
rate
advers
event
includ
asept
mening
thrombot
event
bronchospasm
sepsi
system
inflammatori
respons
host
infecti
insult
sever
sepsi
character
acut
organ
dysfunct
septic
shock
character
hypotens
refractori
fluid
replac
hyperlactatemia
sever
sepsi
septic
shock
repres
one
oldest
press
problem
medicin
care
patient
sepsi
improv
last
decad
howev
incid
sepsi
increas
along
morbid
mortal
rate
especi
critic
ill
adult
worldwid
annual
incid
sever
sepsi
lie
case
per
popul
mortal
sever
sepsi
septic
shock
reach
respect
understand
underli
biolog
featur
sepsi
made
signific
progress
clinic
assess
sever
new
strategi
implement
sepsi
treatment
led
disappoint
result
random
clinic
trial
strategi
modifi
system
inflammatori
respons
sepsi
howev
strategi
show
improv
dramat
surviv
patient
sepsi
develop
highli
purifi
human
plasmaderiv
polyclon
ivig
present
compel
therapi
sever
infect
includ
sepsi
septic
shock
ivig
broad
potent
activ
microorgan
extracellular
product
potent
immunomodulatori
effect
ivig
prepar
particular
igmenrich
prepar
contain
antibodi
lipopolysaccharid
escherichia
coli
pseudomona
aeruginosa
klebsiella
spp
effect
ivig
sepsisinduc
host
respons
seem
pleotrop
yet
complet
clarifi
like
secondari
suppress
synthesi
direct
scaveng
upstream
downstream
mediat
host
respons
complex
immunomodulatori
effect
cellular
effect
immunoglobulin
mediat
igg
constant
fragment
fc
immunoglobulin
act
adaptor
innat
adapt
immun
system
interact
fc
mediat
proand
antiinflammatori
signal
ivig
direct
antibacteri
effect
pathogen
recognit
increas
clearanc
ivig
also
antiinflammatori
properti
mediat
scaveng
bacteri
toxin
proinflammatori
cytokin
immun
cell
deplet
blockad
activ
receptor
modul
express
dendrit
cell
activ
tcell
expans
challeng
pathobiolog
sepsi
associ
acquir
hypogammaglobulinemia
seem
prevent
optim
pathogen
clearanc
pathogen
toxin
scaveng
furthermor
sepsi
caus
endotheli
dysfunct
capillari
leak
togeth
iatrogen
fluid
resuscitationrel
increas
extravascular
volum
eventu
caus
alter
distribut
immunoglobulin
consequ
logic
predict
administr
ivig
sepsi
would
benefit
clinic
set
role
ivig
adjunct
treatment
sepsi
controversi
year
number
random
placebocontrol
clinic
trial
adult
critic
care
patient
evalu
standard
polyclon
ivigor
igmenrich
polyclon
adjunct
therapi
sever
sepsi
well
metaanalys
trial
publish
posit
find
control
trial
anecdot
report
critic
methodolog
weak
includ
small
number
patient
adequaci
blind
recent
studi
meticul
design
shown
much
less
effect
ivig
older
smaller
less
welldesign
studi
note
studi
use
albumin
control
show
less
benefit
ivig
scorebas
immunoglobulin
g
treatment
sepsi
sbit
studi
one
care
design
larg
studi
repres
almost
half
adult
studi
date
show
reduct
mortal
ivig
patient
scoredefin
sepsi
sepsisinduc
multiorgan
failur
first
clinic
trial
evalu
effect
igmaenrich
immunoglobulin
prepar
g
igm
g
iga
g
igg
shown
contain
superior
antibodi
content
bacteri
lipopolysaccharid
appreci
number
neutropen
patient
hematolog
malign
sepsi
septic
shock
show
immunoglobulin
benefici
effect
howev
editor
comment
studi
high
evid
level
demonstr
neutropen
patient
malign
lowgrad
sepsi
one
organ
failur
benefit
adjunct
ivig
treatment
prophylaxi
treatment
neonat
sepsi
major
global
prioriti
larg
intern
trial
carri
test
ivig
group
et
al
mortal
hospit
stay
infant
clinic
suspect
infect
trial
entri
significantli
differ
ivig
treatment
result
intern
neonat
immunotherapi
studi
ini
recent
metaanalys
show
ivig
reduc
mortal
hospit
stay
major
disabl
year
age
infant
sepsi
base
result
ini
trial
subject
routin
administr
ivig
prevent
mortal
infant
sepsi
current
recommend
consid
administr
ivig
sepsi
import
aspect
taken
account
dose
type
time
pharmacokinet
ivig
doserang
studi
complet
studi
use
high
gkg
bodi
weight
dose
ivig
demonstr
better
effect
seem
plausibl
given
clinic
observ
inflammatori
condit
kawasaki
diseas
greater
effect
note
higher
dose
type
ivig
may
import
effect
possibl
favor
greater
pool
effect
igmaenrich
compar
standard
prepar
ivig
igmaenrich
prepar
associ
greater
complement
inactiv
improv
microvascular
perfus
experiment
model
howev
collect
result
anim
model
vitro
experi
show
contradictori
result
allow
definit
conclus
regard
superior
one
specif
immunoglobulin
prepar
patient
sepsi
efficaci
studi
administr
polyval
igg
versu
igma
select
patient
high
risk
sepsi
associ
compar
improv
diseas
sever
regard
time
ivig
administr
sepsi
probabl
window
opportun
first
day
follow
clinic
present
sepsi
window
miss
probabl
success
could
greatli
diminish
pharmacokinet
studi
ivig
sepsi
perform
yet
data
dosag
select
current
practic
primarili
deriv
studi
volunt
patient
primari
immun
defici
indic
immunomodul
exist
pharmacokinet
studi
also
address
immunoglobulin
clearanc
area
curv
paramet
target
serum
immunoglobulin
concentr
addit
still
unknown
whether
main
goal
ivig
sepsi
refil
low
level
endogen
immunoglobulin
altern
whether
ivig
could
exert
benefici
effect
regardless
level
studi
evalu
use
ivig
sepsi
small
methodolog
flaw
highqual
larg
studi
show
effect
given
immunoglobulin
highcost
limit
suppli
lack
strong
evid
support
benefici
effect
wide
use
guidelin
either
neglect
grade
weak
recommend
use
polyclon
ivig
sepsi
clinic
judgment
may
guid
immunoglobulin
use
individu
case
particularli
due
gramneg
etiolog
streptococc
toxic
shock
syndrom
practic
base
larg
theoret
rational
anecdot
retrospect
clinic
observ
effect
monoclon
antibodi
tumor
necrosi
factor
tnf
evalu
seri
trial
differ
therapi
longanticip
sepsi
trial
monarc
monoclon
antitnf
random
control
sepsi
trial
report
afelimomab
made
fab
compon
monoclon
antibodi
patient
sever
sepsi
elev
level
decreas
mortal
safeti
profil
similar
placebo
howev
combin
result
studi
small
improv
mortal
detect
sepsi
increasingli
consid
exagger
poorli
regul
innat
immun
respons
microbi
product
time
diagnosi
entir
network
cytokin
alreadi
activ
regard
result
previou
studi
would
anticip
seem
unlik
therapi
aim
one
cytokin
would
highli
significantli
impact
sepsi
mortal
immunoglobulin
use
wide
medicin
varieti
diseas
includ
infecti
diseas
two
major
indic
immunoglobulin
use
replac
antiinflammatori
therapi
varieti
acut
chronic
autoimmun
diseas
use
prevent
treatment
infecti
diseas
emerg
attract
option
especi
era
multiantibiot
resist
mani
aspect
immunoglobulin
therapi
remain
controversi
contradictori
consequ
immunoglobulin
use
sometim
determin
clinic
judgment
expert
opinion
base
larg
theoret
rational
anecdot
retrospect
clinic
observ
gap
knowledg
need
address
certain
categori
patient
popul
would
benefit
immunoglobulin
treatment
prophylaxi
optim
immunoglobulin
dose
durat
well
time
administr
monoclon
antibodi
technolog
open
new
era
antibodi
therapi
mani
occas
human
monoclon
antibodi
better
therapeut
properti
immunoglobulin
includ
low
toxic
longer
protect
immun
higher
natur
protect
high
specif
sever
antibodi
treatment
bacteri
viral
infect
develop
howev
challeng
need
overcom
becom
prefer
agent
treatment
prophylaxi
infecti
diseas
biofilm
acknowledg
contribut
plethora
chronic
recurr
infect
treatment
erad
biofilmrel
infect
still
challeng
suffici
vitro
preclin
data
support
use
antibodi
direct
extracellular
dnabind
protein
entrap
extracellular
biofilm
polymer
substanc
still
area
ongo
preclin
clinic
research
use
antibodi
constitut
novel
therapeut
approach
treatment
biofilmrel
infect
